News

The patent applications entitled, ‘Compositions to Effect Neuronal Growth,’ include three new compounds and also cover both structure and method claims for inducing neurogenesis and the growth of

The sNDA was submitted to the FDA on 6 May 2011 by Eisai. The submission of the application was supported by the results of Phase III trial compared

The tie up aims to deliver a target list of compounds suitable for taking forward for further development. IVCC chief operating officer Tom McLean said this project joins

The results of the trial suggested that the patients treated with sarilumab in conjunction with methotrexate (MTX) improved signs and symptoms of moderate-to-severe RA compared to patients treated

The IND application seeks permission to conduct clinical trial in human non-patient volunteers. Prior to submitting the IND, the company has conducted meeting with the FDA and the

In the trial, inecalcitol was 11 times potent than a naturally active metabolite of vitamin D, calcitriol in suppressing the growth in-vitro of the human hormone-dependent prostate cancer

Gilead has also entered into a licensing agreement with the Medicines Patent Pool Foundation. The agreement allows the Indian firms to market the generic Elvitegravir, Cobicistat and Quad.

Fondaparinux Sodium Injection is the generic version of GlaxoSmithKline’s (GSK) Arixtra which is indicated as a treatment for acute deep vein thrombosis when administered in conjunction with warfarin

Ursodiol is a generic version of Axcan’s Urso 250mg and Urso Forte tablets. The final approval has been given for Glenmark’s abbreviated new drug application (ANDA) for generic